- Home
- TYRA vs BOE Comparison
TYRA vs BOE Comparison
Compare TYRA & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- BOE
- Stock Information
- Founded
- TYRA 2018
- BOE 2005
- Country
- TYRA United States
- BOE United States
- Employees
- TYRA 38
- BOE N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- BOE Trusts Except Educational Religious and Charitable
- Sector
- TYRA Health Care
- BOE Finance
- Exchange
- TYRA Nasdaq
- BOE Nasdaq
- Market Cap
- TYRA 666.4M
- BOE 699.5M
- IPO Year
- TYRA 2021
- BOE N/A
- Fundamental
- Price
- TYRA $13.17
- BOE $11.35
- Analyst Decision
- TYRA Strong Buy
- BOE
- Analyst Count
- TYRA 6
- BOE 0
- Target Price
- TYRA $30.50
- BOE N/A
- AVG Volume (30 Days)
- TYRA 247.2K
- BOE 166.1K
- Earning Date
- TYRA 03-18-2025
- BOE 01-01-0001
- Dividend Yield
- TYRA N/A
- BOE 7.30%
- EPS Growth
- TYRA N/A
- BOE N/A
- EPS
- TYRA N/A
- BOE N/A
- Revenue
- TYRA N/A
- BOE N/A
- Revenue This Year
- TYRA N/A
- BOE N/A
- Revenue Next Year
- TYRA N/A
- BOE N/A
- P/E Ratio
- TYRA N/A
- BOE N/A
- Revenue Growth
- TYRA N/A
- BOE N/A
- 52 Week Low
- TYRA $11.89
- BOE $8.80
- 52 Week High
- TYRA $29.60
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- TYRA 43.64
- BOE 56.40
- Support Level
- TYRA $12.27
- BOE $11.29
- Resistance Level
- TYRA $13.79
- BOE $11.41
- Average True Range (ATR)
- TYRA 0.71
- BOE 0.11
- MACD
- TYRA 0.03
- BOE 0.00
- Stochastic Oscillator
- TYRA 51.09
- BOE 70.00
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.